menu
    • menu

    Company profile for Ensho Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ensho Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing breakthrough oral therapies for inflammatory diseases, particularly inflammatory bowel disease (IBD). Our lead candidate, NSHO-101, is an oral, selective small molecule inhibitor targeting the integrin α4β7, aiming to provide a gut-restricted treatment for conditions like ulcerative colitis and Crohn's disease. Having demonstrated safety...
    Ensho Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing breakthrough oral therapies for inflammatory diseases, particularly inflammatory bowel disease (IBD). Our lead candidate, NSHO-101, is an oral, selective small molecule inhibitor targeting the integrin α4β7, aiming to provide a gut-restricted treatment for conditions like ulcerative colitis and Crohn's disease. Having demonstrated safety and target engagement in Phase 1 trials, NSHO-101 is set to enter Phase 2 clinical development in the first half of 2025.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ensho TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    422 Mountain Way, Morris Plains, NJ 07950
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.enshorx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Young Biotech Exec’s Early Stand Proved Her Leadership Mettle
    Young Biotech Exec’s Early Stand Proved Her Leadership Mettle

    31 Oct 2025

    // BIOSPACE

    https://www.biospace.com/business/an-early-career-stand-proved-this-young-biotech-exec-had-what-it-takes

    BIOSPACE
    31 Oct 2025
    Share Share
    Ensho Presents NSHO-101 Data For IBD At ECCO 2025
    Ensho Presents NSHO-101 Data For IBD At ECCO 2025

    21 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/21/3030459/0/en/Ensho-Therapeutics-Announces-Presentation-of-Data-Highlighting-NSHO-101-as-a-Once-Daily-Oral-Agent-for-the-Potential-Treatment-of-Inflammatory-Bowel-Disease-at-ECCO-2025.html

    GLOBENEWSWIRE
    21 Feb 2025
    Share Share
    Ensho To Present Ph1 NSHO-101 Data For IBD At ECCO 2025
    Ensho To Present Ph1 NSHO-101 Data For IBD At ECCO 2025

    14 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/14/3026687/0/en/Ensho-Therapeutics-Announces-Upcoming-Presentation-at-ECCO-2025-of-Phase-1-Once-Daily-Dosing-Data-for-NSHO-101-an-Oral-%CE%B14%CE%B27-Inhibitor-for-Inflammatory-Bowel-Disease.html

    GLOBENEWSWIRE
    14 Feb 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search